Immun Checkpoint Washout in Patients With Invasive Ductal Breast Cancer

Recruiting N/A Interventional Study
Breast Cancer Metastatic Breast Carcinoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Study type
Interventional
Purpose
Diagnostic
Participants needed
30 (estimated)
Sponsor
Istanbul Training and Research Hospital · Government
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Invasive ductal carcinoma is the most common type of invasive breast cancer. In cases where axillary lymph node metastases are diagnosed through screening, they can be found in up to 25% of cases, and in symptomatic cases, up to 60% of cases. The clinical detection accuracy of axillary lymph node metastases is only 33%. Accurate staging of lymph nodes in breast cancer patients is crucial for both …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Histopathologically proven invasive ductal carcinoma * Patients who will have neoadjuvant therapy Exclusion Criteria: * The fine-needle aspiration biopsy (FNAB) result of the suspected metastatic lymph node is negative. * The FNAB result of the presumed healthy lymph node is…
Contacts

Ufuk Oguz Idiz, Assoc. Prof. MD. PhD

+905062044714

ufukidiz@gmail.com

CONTACT

Mert Ali Dolek, MD

+905364310364

mertdolek@gmail.com

CONTACT